Persistent avascular retina following intravitreal ranibizumab injection for type 1 retinopathy of prematurity: incidence, risk factors, and refractive outcomes
Delta Journal of Ophthalmology · 2026-10 · 27 (4) · 301-310
DOI: 10.4103/djo.djo_23_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Delta Journal of Ophthalmology, online erschienen am 19.11.2026. Verfasst von Ahmed G. Elgharieb und 4 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
The aim of this study was to identify the incidence and neonatal and maternal risk factors for persistent avascular retina (PAR) after intravitreal ranibizumab injection for type 1 retinopathy of prematurity (ROP) and to compare the refractive and biometric outcomes in the eyes treated with or without additional laser photocoagulation for vascular leakage. Patients and methods A prospective planned double-armed, interventional, nonrandomized comparative study was conducted at Mansoura Ophthalmic Center, Mansura, Egypt on 80 eyes of 40 premature infants diagnosed with type 1 ROP and treated with a single baseline dose of intravitreal injection of ranibizumab (0.25 mg in 0.025 ml). Some of the eyes required more than one injection for either persistence (four eyes=5%) or reactivation (eight eyes=10%). The follow-up examinations included indirect ophthalmoscopy, Ret Cam imaging, and fundus fluorescein angiography (FFA) at 60 weeks postmenstrual age to assess the extent of PAR and associated vascular leakage. Cases with leakage extending beyond two clock hours or showing progressive expansion across the sequential frames underwent diode laser photocoagulation of the avascular zones. The axial length (AL), keratometry, and cycloplegic refraction were measured at 1, 3, and 6 months after treatment.
Results
All treated eyes showed PAR by 60 weeks postmenstrual age. FFA leakage was confirmed in 41 (51.25%) cases, whereas 39 (48.75%) cases presented with PAR without any active leakage on angiography. Larger PAR size was linked to longer neonatal intensive care unit stays ( P =0.018), more blood transfusions ( P =0.025), number of injections ( P
Zitieren
APA
Elgharieb, A. G., Mohsen, T. A., El-Said, E., Shahin, M. M., & Abdelkader, A. M. (2026). Persistent avascular retina following intravitreal ranibizumab injection for type 1 retinopathy of prematurity: incidence, risk factors, and refractive outcomes. Delta Journal of Ophthalmology, 27(4), 301-310. https://doi.org/10.4103/djo.djo_23_26
Vancouver
Elgharieb AG, Mohsen TA, El-Said E, Shahin MM, Abdelkader AM. Persistent avascular retina following intravitreal ranibizumab injection for type 1 retinopathy of prematurity: incidence, risk factors, and refractive outcomes. Delta Journal of Ophthalmology. 2026;27(4):301-310. doi:10.4103/djo.djo_23_26
BibTeX
@article{Elgharieb2026,
author = {Elgharieb, Ahmed G. and Mohsen, Tarek A. and El-Said, Eglal and Shahin, Maha M. and Abdelkader, Amr M.E.},
title = {Persistent avascular retina following intravitreal ranibizumab injection for type 1 retinopathy of prematurity: incidence, risk factors, and refractive outcomes},
journal = {Delta Journal of Ophthalmology},
year = {2026},
volume = {27},
number = {4},
pages = {301--310},
doi = {10.4103/djo.djo_23_26}
}
EUVIMED